The Real Story

2017 was a year when we all saw truth come under attack.  Whether in politics or business, “fake news” became mainstream media and many people and companies became victims.  One such company was Proove Biosciences.  On this site, I am doing an expose to show the world how those ex-employees and consultants made up false allegations, convinced an irresponsible journalist to publish them, and the harmful storm that ensued.  Everything published on this website can be supported by primary sources – empirical evidence.  That makes this site stand in strong contrast to the lies spread by other sources.  Check it out for yourself.  Facts are indeed stubborn things.

Question from Andrew Keeler, Answers from Brian Meshkin

Interview with Brian

So tell me about Proove?

“Proove was the leader in precision medicine for the nation’s most prevalent and most expensive healthcare condition – chronic pain.  Precision medicine, as defined by NIH, involves the analysis of genetic, lifestyle, and environmental factors to better understand health so that you can give a patient the best treatment possible.  I founded the company with this social mission – knowing that if we could deliver on the promise of precision medicine for such a large condition – we could have a huge impact on almost every patient in the world.  I started Proove in December 2009 and by 2015, we were 170 employees at $17M in revenue. And by 2016, we were 278 employees and $28M in revenue.   We invested heavily in R&D – over $20M – and we transferred technology from some leading academic centers including UNC Chapel Hill and the University of Utah.  Our unique R&D model was based on our name – Proove.  Proove’s testing helped doctors understand patient pain perception, risk for opioid abuse, and which medications would work best for the individual patient.  We literally tracked the outcomes for almost every patient tested by Proove in order to prove how the doctor used the test and whether the patient improved.  Based on data across various insurance types – Medicare, Cigna, Blue Shield of California – you name it, about 90% of patients had an average pain reduction of about 3.5 points on a self-reported scale – or about 40% to 50% in less than 90 days. I am so proud of what we achieved – with over 150,000 patients tested and incredible outcomes, it is very rewarding to know we made such a positive impact.  Our data was so strong and research so extensive that we won numerous awards from medical societies for our research.  With the leading researchers in pain genetics working with us, we did great things.”

To learn more about Proove’s achievements, Click Below

Question: So after all these good things, what happened with Proove?

Answer “Over the past year, I’ve been asked that question many times.  It’s a painful but fair question. How could a company that was doing so many great things suddenly be under serious attack and fall?  Under advice of counsel, I’ve chosen to keep quiet so that no one could ever suggest that I was interfering with a governmental inquiry.  In doing so, those who have created false allegations and the purveyors who have spread them have been unanswered, and they have celebrated in the destruction they have caused.  My attorney refers to their actions as “corporate terrorism.”  But now that the government inquiry has spent 7 months going through company records and materials, and of course, found no wrongdoing, it’s time to set the record straight. My silence ends today and now the documentable, empirical evidence will now be shared.” 

To learn more about Proove’s response to the allegations, Click Below








Question: You must be so upset.  Why didn’t you respond to the allegations sooner?

Answer: “That’s a good question.  Looking back, it was probably a mistake not to respond to the Piller articles sooner.  Our thought was to “take the high road” as the accusations were so outlandish.  And despite sending Piller information, he clearly had an agenda and chose to ignore primary sources.  After his first article, our attorneys suggested we not respond to his further questions.  We probably should have responded with force earlier, as the second story wouldn’t have caused so much damage.  He’s actually a very pleasant guy to speak with over the phone. I’ve never met him in person, and don’t know why he had an agenda.  But clearly he did.  In speaking with the guys who hired and fired him years ago at the LA Times, they said that his reputation was as a journalist who couldn’t quite deliver the goods. So, I guess this is just another example.  Once those allegations piqued the government’s curiosity, we had to respond and we posted a corporate response.  And then when the FBI showed up with a subpoena, it was truly ironic.  I told them how ironic it was that Proove had the only technology with peer-reviewed published evidence to help solve the dueling health crises of chronic pain and opioid abuse – a cause that we should working together with the Department of Justice on solving – yet they were wasting their time looking into false allegations instead of working together with us to help people.  We obviously cooperated with the government – as we always had.  However, never in a million years, did I ever think that false allegations from disgruntled ex-employees would be given any credibility. Unfortunately, they were given an audience.  And so employees that I had personally helped – whether it was paying off Bruce’s credit cards and giving him money for a housing down payment, or paying for Rhonda’s mother’s funeral and internment, or you name it, all of those good deeds came back to bite me as those became the people who spread the lies.”

To learn more about the conspirators who devised the lies, click below.

Q: Only a couple more questions, and I appreciate you giving me so many sources to use.  I’m interested in how you explain the criticisms from credible scientists or physicians in the articles?


A: “That’s a great question. As I shared with Piller, it is fair for scientists or physicians to share criticisms.  It’s part of the scientific debate.  At the time of the first article, Proove only had a few peer-reviewed, published studies to support its science and about 100 scientific posters.  I shared that we had a bunch in press to be published. And since then, I believe about 10 papers have been published in peer-reviewed journals.  So, you have another huge irony.  You have other copy-cat companies out there doing small studies with 60 patients or 100 patients, having two posters and one peer-reviewed publication, and the media reports that as “Scientifically Validated” but Proove with multiple studies with over 10,000 patients, have 100 posters, research awards, and over 10 peer-reviewed studies was represented as not scientifically valid.  It’s actually quite silly.  But I’ve come to learn that journalists are not always interested in the truth or facts, but rather a more controversial story.  Another crazy accusation was the criticism of Proove’s research.  Good research generally follows a pattern and Proove’s research was consistent with Good Clinical Practices.”


To learn more about how the “Big Lie” spread and how false those accusations are click below

Genetic Test Can Help Prevent America’s Opioid Painkiller Addiction | The Pulse | CNBC

CNBC Published on Sep 7, 2016 Proove Biosciences has developed a series of medical tests that can show a doctor who is at a high risk for developing addiction to opioid painkillers. » Subscribe to CNBC:  About CNBC: From 'Wall...

News Conference at APPM Regarding Presidential Candidates, Doctors, and Opioid Abuse

PRConsultant Published on Feb 19, 2016 With prescription drug and heroin overdoses now killing more Americans than car accidents, the opioid crisis has worked its way into the speeches of presidential candidates and a billion dollar plan by President...

October 24, 2013 – Proove Release: Proove Sponsors National Take Back Day

Proove Biosciences Announces Sponsorship of National Drug Take Back Day and HC DrugFree IRVINE, CA (PRWEB) October 24, 2013 Proove Biosciences, the leader in personalized pain medication innovation, is proud to be a Silver Sponsor partner of HC DrugFree and...

April 15, 2014 – Proove Release: Proove Wins Award from American Society of Interventional Pain Physicians for Its Research

Proove Biosciences' Presented Research on the Predictive Risk of Workers Compensation Claims Extending Beyond One Year Irvine, CA (PRWEB) April 15, 2014 Proove Biosciences, the leader in Personalized Pain Medicine testing services, exhibited and presented three...

April 21, 2014 – Issued by the American Academy of Neurology recognizing Proove’s quality research

Low Tolerance for Pain? The Reason May Be In Your Genes Apr 21, 2014, 15:15 ET from American Academy of Neurology ------------------------------------------------------------------------------------------------------- PHILADELPHIA, April 21,...

April 7, 2015 – Proove Release: Proove Launches Opioid Response Test

(PRWEB) APRIL 07, 2015 Proove Biosciences a commercial and research leader in Personalized Medicine, is excited to announce the launch of Proove Opioid Response - the world’s first clinical laboratory test to predict responders to opioid pain medications. Building on...

April 23, 2015 – Proove Release: Proove Biosciences Launches World's First Test To Predict Responders To Commonly Prescribed Non-Opioid Pain Medications

The new Proove Non-Opioid Pain Medication Response profile evaluates genetic factors to predict a patient’s response to non opioids before prescribing Irvine, CA (PRWEB) - Proove Biosciences, a commercial and research leader in Personalized Medicine, is excited to...

July 14, 2015 – Proove Release: Proove Biosciences Presents Research Studies at Neurological Disorders Summit in San Francisco, CA

Irvine, CA (PRWEB) July 14, 2015 Proove Biosciences, a commercial and research leader in Personalized Medicine, recently presented data on three ground-breaking scientific studies at the Neurological Disorders Summit in San Francisco, CA. The Neurological Disorders...

October 23, 2015 – Proove Release: Proove Partners with USC to Conduct Research

Proove Biosciences, a commercial and research leader in personalized medicine, is excited to announce their partnership with the Keck Medicine of the University of Southern California(USC) Pain Center to study the genetics of chronic pain. The T.R.O.J.A.N. Study...